A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
← catalyst calendarNCT07210723 · readout ≤ 407 d
Sponsored by Kardigan, Inc. (industry) · KARD — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
332estimated
Sites
78
Countries
Belgium, Denmark, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-13 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Genetic Dilated Cardiomyopathy
Interventions
- Drug: danicamtiv
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1
measured 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1
measured 26 weeks
Permalink · KARD's whole pipeline · Catalyst calendar · Every registered study · What changed